Bibliographic Details
| Title: |
Author Correction: Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization. |
| Authors: |
Hong-Nguyen, Yugenia K., Toerner, Joseph, Lee, Lucia, Allende, Maria C., Kaslow, David C. |
| Source: |
NPJ Vaccines; 3/5/2025, Vol. 10 Issue 1, p1-1, 1p |
| Subject Terms: |
PREGNANT women, RESPIRATORY syncytial virus infections, STATISTICAL significance, NEONATAL death, INFANT diseases, PREMATURE labor |
| Abstract: |
The correction notice in the NPJ Vaccines journal addresses inaccuracies in an article about preventing infant RSV disease through maternal immunization. The corrections clarify that RSVPreF3-Mat, not Arexvy, was used in GlaxoSmithKline Pharmaceuticals' maternal immunization program. It also notes that while there was a higher number of neonatal deaths associated with preterm births in the RSVPreF3-Mat group, this was likely due to an imbalance in preterm births rather than the vaccine itself. The corrections do not alter the scientific conclusions of the original article. [Extracted from the article] |
|
Copyright of NPJ Vaccines is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
